Clozapine

Quick links to important sections

Clozapine

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Clozapine

Property Description
Active ingredient Clozapine
Form Tablet, Orally Disintegrating Tablet, Oral Suspension
Pharmacological class Atypical Antipsychotic (Second-Generation)
General purpose Stabilization of persistent, severe thought imbalances
Origin Synthetic, derived from tricyclic dibenzodiazepine

Clozapine: Definition and Classification as an Atypical Antipsychotic

Clozapine is a psychotropic agent officially classified as an Atypical Antipsychotic, also known as a Second-Generation Antipsychotic. The active ingredient, Clozapine, is a synthetic compound derived from the tricyclic dibenzodiazepine chemical structure. Clozapine is historically significant as the first drug in its class, setting it apart from older medications by demonstrating a unique pharmacological profile. Clozapine's unique receptor binding profile is associated with a significantly low potential for causing movement disorders. This means the drug offers a recognized benefit regarding certain motor side effects compared to many first-generation alternatives.

What are the Available Forms and Composition of Clozapine?

Clozapine is a single active ingredient product designed for oral administration, meaning the entire therapeutic effect comes from the Clozapine compound alone. The medication is presented in several distinct, high-level dosage forms, including the traditional compressed tablet, the Orally Disintegrating Tablet (ODT) (marketed under names such as FazaClo), and a liquid Oral Suspension (such as Versacloz). This availability of different formats, including an ODT that dissolves quickly in the mouth, is a key differentiating feature designed to aid administration in various patient settings. The final composition involves the active drug substance combined with necessary inert materials, such as solid excipients for the tablets or aqueous bases and suspending agents for the liquid format.

What is the General Purpose of Clozapine?

The general purpose of Clozapine is to stabilize and normalize thought patterns in individuals experiencing severe forms of mental imbalance that have not responded adequately to standard treatments. Clozapine provides efficacy in managing persistent, treatment-refractory symptoms for specific patient populations. This efficacy in difficult cases is achieved through the unique action of rebalancing key brain messengers, primarily serotonin and dopamine, within the central nervous system. Its distinctive functional profile and mechanism make it a valuable option for providing relief from persistent, severe psychotic symptoms.

Regulatory References

  1. Clozapine for Schizophrenia: NCBI/NIH Bookshelf
  2. Clozapine MedlinePlus Drug Information

What side effects are possible with Clozapine?

Clozapine: Possible Side Effects and Safety Information

Clozapine's official safety profile is strongly defined by the mandated monitoring requirements for hematological risks, primarily the potential for agranulocytosis (a severe drop in white blood cells). This serious risk necessitates continuous blood count testing under regulatory safety programs as a strict condition of use.


Adverse reactions are officially categorized by frequency and organ system, reflecting data compiled by government authorities.

Classification Examples of Reactions
Very Common Tachycardia, Drowsiness, Dizziness, Constipation, Hypersalivation
Common Weight gain, Tremor, Orthostatic Hypotension, Headache

Beyond the most common effects, regulatory documentation highlights several Serious Adverse Reactions, including Myocarditis and Cardiomyopathy (heart muscle conditions), and the potential for Seizures/Convulsions.

Time-related patterns are noted in the official labeling, stating that the risk of Orthostatic Hypotension and the onset of Agranulocytosis is higher during treatment initiation and dose escalation. Conversely, metabolic changes such as significant weight gain are associated with long-term exposure.

Furthermore, official safety statements include specific constraints for certain populations, such as the documented increased mortality risk for older adults treated for dementia-related psychosis. The medicine is also typically restricted in individuals with a history of clozapine-induced agranulocytosis or severe active liver disease.

Overdose and Emergency Response

Clozapine Overdose and When to Seek Help

Official regulatory documents describe a Clozapine overdose as presenting with clinical signs of both Central Nervous System (CNS) depression and CNS excitation. Documented manifestations commonly include profound drowsiness, lethargy, confusion, delirium, and convulsions (seizures). Autonomic effects such as hypersalivation, mydriasis (pupil dilation), and thermolability are also noted in regulatory labeling.

Life-threatening outcomes cited in official documents primarily involve the cardiovascular and respiratory systems, including hypotension, cardiac arrhythmias, respiratory depression or arrest, and progression to coma. Fatalities have been reported, often associated with severe cardiopulmonary events such as cardiac failure or aspiration pneumonia.

Immediate medical attention must be sought for any suspected or known overdose. Close medical supervision is required for at least five days due to the possibility of delayed severe reactions. Treatment is strictly limited to symptomatic and supportive measures, as no specific antidote is known. Regulatory guidance specifically mandates that continuous cardiac monitoring and surveillance of respiration are required. The use of epinephrine should be avoided in treating any associated hypotension due to the risk of paradoxical effects.

Therapeutic Uses of Clozapine

What Clozapine Treats: Main Uses and Benefits

Clozapine is commonly used to help achieve significant symptomatic relief in cases of schizophrenia where core psychotic features, such as persistent delusions and hallucinations, have failed to respond to two or more prior drug trials. Its primary therapeutic indications include treatment-resistant schizophrenia and the reduction of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. This targeted application contributes to easing the intensity and burden of severe, enduring symptoms.

The medication is applied to manage high-risk behavioral patterns, and is relevant for easing the risk of recurrent suicidal behavior. Furthermore, it is applied in clinical contexts to mitigate symptoms of hostility, aggression, and violence associated with the severe illness, and may assist with maintaining stability, which is often relevant for easing the need for hospitalization. Clozapine is also relevant for patients who require symptom control but cannot tolerate the motor side effects of other antipsychotics, offering the comfort benefit of a lower potential for extrapyramidal symptoms (EPS).

Quick Fact: Relief for Intractable Psychotic Symptoms (Delusions and Hallucinations)

Eligibility and Restrictions for Use

Who can and cannot use Clozapine?

Clozapine is approved for use in adults who require treatment for specific conditions, such as treatment-resistant schizophrenia or the reduction of recurrent suicidal behavior in schizophrenia or schizoaffective disorder. Eligibility is determined by strict regulatory criteria.


Absolute Contraindications (Must Not Use)

Individuals with certain pre-existing conditions are formally contraindicated from using clozapine due to significant risks, according to regulatory labels (e.g., FDA, EMA). This includes:

  • A history of Clozapine-Induced Agranulocytosis or Severe Neutropenia.
  • Pre-existing conditions like Impaired Bone Marrow Function or Myeloproliferative Disorders.
  • Severe, uncontrolled conditions such as Uncontrolled Epilepsy, Paralytic Ileus, or Severe Heart Disease (e.g., active myocarditis).

Restricted and Non-Recommended Populations

Population/Condition Regulatory Status
Pediatric Patients (Under 16) Safety and effectiveness not established.
Older Adults (Dementia-related psychosis) Not approved; increased risk of mortality.
Severe Organ Impairment (Hepatic/Renal) Conditional use; requires caution and monitoring.
Breastfeeding Women Use is not recommended.

What should I know about interactions with other medicines?

Clozapine's official interaction profile is documented to involve both pharmacokinetic alteration and additive pharmacodynamic effects. The regulatory information establishes formal constraints for co-administration.

Formal Restrictions and Exposure Risks

Several combinations are formally documented as restricted. Co-administration with agents such as Nirmatrelvir/Ritonavir, Dronedarone, and Thioridazine is classified as contraindicated due to severe risks like clozapine toxicity or QTc interval prolongation. The concurrent use of Strong CYP3A4 Inducers is additionally noted as not recommended.

The metabolism of Clozapine is highly sensitive to external agents that affect the CYP1A2 enzyme. Strong inhibitors of this enzyme, such as Fluvoxamine or Ciprofloxacin, are documented to cause a significant increase in clozapine plasma concentrations. In contrast, inducers of CYP1A2, such as Tobacco Smoke, cause a decrease in plasma concentrations. The consumption of large amounts of Caffeine may also increase serum concentrations due to metabolic inhibition.

Additive Pharmacodynamic Risks

Documented pharmacodynamic interactions create additive physiological risks across several systems. Central nervous system (CNS) depressants, including alcohol, may result in additive CNS depression, and the consumption of alcohol should be avoided. Other documented additive effects include an increased risk of anticholinergic toxicity when combined with anticholinergic drugs, and an increased risk of orthostatic hypotension when combined with antihypertensive medications. These interaction patterns establish clear regulatory constraints on co-administration.

Mechanism of Action

Clozapine is a multi-receptor agent that operates by influencing several key communication systems in the central nervous system (CNS) simultaneously, resulting in a broad modulation of neural signaling. The entire physiological effect profile is derived from this unique, complex pattern of molecular interactions.

Multi-Receptor Neurotransmitter Rebalancing

The primary mechanism involves a distinctive combination of actions on dopamine (D2, D4) and serotonin (5-HT2A) receptors. Clozapine exerts antagonism of the 5-HT2A receptor alongside only transient, low-affinity blockade of the D2 receptor. This distinctive ratio re-regulates dopamine activity in specific cortical regions, modulating neural circuit activity, and allowing the preservation of function in the nigrostriatal pathway.


Support for Regulatory Pathways

The drug's activity extends to systems governing neural processing, notably the cholinergic and glutamatergic pathways. The active metabolite uniquely acts as an M1 agonist, while the parent drug influences glutamatergic signaling by increasing synaptic glycine. This synergy modulates regulatory feedback loops and influences processes within the CNS.


Broad System Modulation and Constraint

Clozapine possesses high affinity for numerous other targets, including histamine H1 and alpha-1 (alpha1) adrenergic receptors. The blockade of these receptors modulates the central arousal system and influences autonomic controls, such as vascular tone. This broad, multi-system action is the source of its distinct functional profile and physiological constraints.

Dosage and Administration Information

Clozapine is administered orally and must be used according to a defined sequence of dosage steps and administration rules. Treatment begins with a very low initial dose and uses a gradual increase schedule.

Official Dosing and Administration

Usage Instruction Official Guideline
Initial Starting Dose 12.5 mg once daily or twice daily.
Titration and Target Dose The daily dose is increased in 25 mg to 50 mg increments per day to reach a target range of 300 mg to 450 mg per day by the end of two weeks.
Maximum Daily Dose The maximum recommended daily dose is 900 mg.
Dose Timing The total daily dose is typically administered in divided doses; the larger portion is often taken at bedtime. It may be taken with or without food.

Administration Requirements and Special Populations

Clozapine is available as conventional tablets, an orally disintegrating tablet (ODT), and an oral suspension. The ODT can be allowed to disintegrate in the mouth or chewed, and no water is necessary for administration.

For older adults (geriatric patients), a lower starting dose (12.5 mg/day) and a slower titration schedule are utilized. Patients with renal or hepatic impairment also require a lower starting dose and cautious, gradual dose increases.

Course Duration and Interruption

If the administration of clozapine is interrupted for more than two days (48 hours), the dose must be re-initiated at the starting dose of 12.5 mg once or twice daily. When planned, termination of treatment should involve a gradual dose reduction over a one- to two-week period.

Recent Clinical Evidence

Research evidence / Overview of Studies for Clozapine

The core body of research for this medicine was studied for individuals with schizophrenia whose symptoms had persisted despite treatment with two or more previous medications, a group often defined in research as having treatment-resistant schizophrenia (TRS).

Researchers used numerous Randomized Controlled Trials (RCTs), supplemented by large-scale Systematic Reviews and Meta-analyses. The study designs were used in observational settings evaluating daily-life functioning and applied in studies examining patient-reported experiences.

The studies monitored outcomes such as changes in overall symptom intensity, the frequency of relapse events, and patient-reported outcomes describing perceived discomfort or quality of life. Findings describe patterns observed in the studies where research examined different treatment contexts.

Evidence for Reducing Recurrent Suicidal Behavior

A dedicated and pivotal Randomized Controlled Trial (RCT), along with several large-scale Cohort Studies, was used to research patterns related to persistent or recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder. This research examined specific outcomes describing episodic or acute changes in behavior linked to suicide risk.

Findings describe patterns observed in the studies related to outcomes capturing phases of heightened symptom activity. However, research suggests that the statistical outcome for very rare events, such as completed suicide, was not achieved in the main RCT, meaning the evidence on this specific outcome is limited and heterogeneous.

Evidence for Patients Intolerant of Movement Side Effects

Research examined specific movement disorder scales, such as the involuntary movement disorders (Extrapyramidal Symptoms or EPS). This research includes comparative RCTs and Systematic Reviews that monitored outcomes related to physical discomfort and neurological strain.

The studies report how symptoms evolved in the observed populations. Findings indicate that the medicine was studied for and showed patterns related to outcomes related to physical discomfort were examined against older first-generation antipsychotics. However, comparative evidence is limited when research examined differences in motor side effect potential against every other newer second-generation agent.

Research Gaps and Unanswered Questions

Despite the extensive research record, evidence quality varies across studies, and several areas remain either unstudied or need further clarification:

  • Limited Comparative Data: Comparative evidence is lacking for a comprehensive, head-to-head evaluation against every single newer second-generation antipsychotic agent in the treatment-resistant population for primary efficacy.
  • Function and Cognition Outcomes: There is limited information for long-term outcomes related to detailed measures of cognitive function and social recovery across the entire patient population.

Key Studies & References Examining the safety profile of clozapine versus other antipsychotics: systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Clozapine (FAQ)


Q: What are the warning signs of a serious bowel problem caused by Clozapine?

Regulatory documents describe the possibility of serious gastrointestinal issues, including severe constipation and a condition called paralytic ileus. Warning signs that may be noted include difficulty passing stool or gas, severe abdominal pain, or significant bloating. If these symptoms are experienced, official guidance indicates the need for prompt evaluation.


Q: Can Clozapine cause fever or flu-like symptoms?

Yes, official warnings mention that fever and flu-like symptoms, such as chills or a sore throat, can occur. These symptoms are described as potential signs of serious adverse reactions, specifically a severe drop in white blood cell count (neutropenia) or heart muscle inflammation (myocarditis). Official safety information emphasizes that any fever experienced should be promptly discussed with a healthcare provider.


Q: What are the risks of suddenly stopping Clozapine treatment?

Official prescribing information advises against abrupt discontinuation of this medication. Abrupt discontinuation of Clozapine is associated with the potential for a rapid return of psychotic symptoms, sometimes referred to as rebound psychosis. It may also lead to the re-emergence of certain movement disorders due to a rebound effect on brain chemicals.


Q: Can Clozapine affect my blood sugar levels or lead to diabetes?

Yes, regulatory documents indicate that Clozapine is associated with significant metabolic changes. These changes can include elevated blood sugar (hyperglycemia) and the potential development of diabetes mellitus, even in individuals without a prior history of the condition. Official information recommends monitoring blood glucose levels during treatment.


Q: Does Clozapine interact with common over-the-counter pain relievers?

While regulatory warnings do not list every single over-the-counter (OTC) pain reliever, they advise caution regarding combinations. There is a documented risk of additive effects, such as increased sedation or enhanced anticholinergic side effects, when Clozapine is taken with agents that possess similar properties.


Q: Can Clozapine interact with herbal supplements like St. John's Wort?

Official information indicates that Clozapine's levels in the body are sensitive to substances that affect certain liver enzymes, such as CYP1A2 and CYP3A4. Since St. John's Wort is widely known to affect these enzymes, regulatory principles suggest it could significantly decrease the concentration of Clozapine, potentially reducing its effect.


Q: Are there any dietary restrictions or foods to avoid while on Clozapine?

The official product information notes a specific concern regarding caffeine consumption. Drinking large amounts of caffeine may increase the amount of Clozapine in the bloodstream, which could raise the risk of side effects. Outside of this, the medication can generally be taken with or without food.


Q: Is Clozapine treatment possible during pregnancy?

Official labeling contains specific warnings about the use of Clozapine during pregnancy. It is noted that exposure to the drug during the third trimester may lead to risks for the newborn, including symptoms of breathing difficulty and agitation (withdrawal symptoms). Decisions regarding use during pregnancy require careful assessment by a healthcare professional.


Q: Can Clozapine cause problems with urination or bladder control?

Regulatory documents indicate that Clozapine has anticholinergic properties, which can sometimes interfere with bladder function. Because of this effect, certain adverse reactions such as difficulty with urination (urinary retention) are listed in the safety information, particularly when combined with other similar medications.


Q: What is meant by 'Clozapine-induced eosinophilia'?

Clozapine-induced eosinophilia is an adverse reaction described in official documents as an increase in eosinophils, which are a specific type of white blood cell. This reaction often occurs early in treatment and is usually temporary, but it requires monitoring as per regulatory guidelines.


Q: Are there any long-term effects of Clozapine on liver or kidney function?

Official information emphasizes that individuals with pre-existing hepatic (liver) or renal (kidney) impairment require cautious use and careful dose adjustment. Regulatory guidelines specify that regular monitoring of liver function tests is necessary during the course of treatment.


Q: Does Clozapine help with negative symptoms of schizophrenia?

Clozapine is officially indicated for treatment-resistant schizophrenia. The research supporting the official use included the monitoring of outcomes related to both positive and negative symptoms of the condition.


Q: What is the recommended approach if a person experiences sedation or daytime sleepiness on Clozapine?

Drowsiness or sedation is listed as a very common reaction to Clozapine. To address this, the official dosing instructions note that the total daily dose is typically divided, and the larger portion of the dose is often directed to be taken at bedtime.


Q: Is it safe to drive or operate machinery while initiating Clozapine treatment?

Official warnings state that this medication may impair the mental and physical ability needed to perform hazardous tasks, such as driving a car or operating machinery. This caution is particularly relevant during the initial phases of treatment or following dose increases.


Q: Does Clozapine have a known effect on sexual function?

Regulatory documents include reports of sexual dysfunction, such as difficulties with ejaculation, within the list of adverse reactions. This information comes primarily from post-marketing reports and specific adverse reaction listings.


Q: Is it necessary to avoid alcohol completely when taking Clozapine?

Official regulatory information advises that alcohol should be avoided while using Clozapine. The combination is noted to enhance the effects of the medication, potentially leading to significant sedation due to an additive central nervous system (CNS) depressant effect.


Q: Can Clozapine cause restlessness or involuntary movements?

While Clozapine is often noted for a low risk of causing certain severe movement disorders, the regulatory adverse reaction lists do include reports of general restlessness. In rare cases, more serious involuntary movement disorders have also been reported.


Q: Does taking Clozapine affect the use of nicotine replacement therapies?

Official warnings regarding smoking are focused on chemicals in tobacco smoke that reduce Clozapine levels via a liver enzyme. Nicotine itself, when delivered through nicotine replacement therapies (NRTs) like patches or gum, is not documented in regulatory information to have the same effect on Clozapine levels as smoking.


Q: What are the potential side effects of combining Clozapine with certain antibiotics?

Official warnings highlight that certain antibiotics, particularly those that inhibit the CYP1A2 liver enzyme, can increase the concentration of Clozapine in the bloodstream, raising the risk of toxicity.


Q: Can Clozapine cause dry mouth or blurred vision?

Yes, official adverse reaction lists include both dry mouth and blurred vision. These effects are associated with the medication's anticholinergic properties (blocking certain chemical messengers) and are listed as common reactions.


Q: What are the symptoms of a serious allergic reaction to Clozapine?

Official documents list drug hypersensitivity (a severe allergy) as a condition that prevents use. Symptoms of a serious allergic reaction may include difficulty breathing, severe skin rash, or swelling of the face, tongue, or throat, which require emergency medical attention.


Q: Does Clozapine affect cholesterol levels?

Clozapine is officially associated with metabolic changes, which include alterations to blood fats (lipids). Increases in both cholesterol and triglycerides are documented in the safety profile, and regulatory guidelines recommend the periodic monitoring of fasting lipid profiles.


Q: What are the risks of taking Clozapine if I already have low blood pressure?

The official information notes that Clozapine can cause orthostatic hypotension (a drop in blood pressure when changing posture). This effect is noted as a particular concern, and regulatory information requires cautious use in individuals with pre-existing low blood pressure or cardiovascular issues.


Q: Why is there a need to monitor blood levels of Clozapine (therapeutic drug monitoring)?

Regulatory documentation acknowledges that Clozapine levels vary widely among individuals, and the therapeutic effect is associated with maintaining concentrations within a certain range. Monitoring the drug concentration in the plasma is used to help assess cases of non-response or to check for potential toxicity.


Q: How is a low white blood cell count managed during Clozapine treatment?

Official regulatory protocols mandate that if a patient's white blood cell count (WBC) or Absolute Neutrophil Count (ANC) falls below pre-specified thresholds, the medication must be immediately interrupted or discontinued. Close monitoring for signs of infection is also specified as mandatory in this situation.

How should Clozapine be stored and disposed of?

Storage and Disposal Requirements for Clozapine

Clozapine (tablets and orally disintegrating tablets) must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and stored away from moisture, kept in its original, tightly closed container.

Stability and Handling

The oral suspension form must not be refrigerated or frozen. Once opened, the suspension has a limited stability period and must be discarded after 100 days.

Safety and Disposal

All forms of the medicine must be kept out of the reach of children. Unused or expired Clozapine must be disposed of according to local regulations; it should not be thrown into household trash or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Clozapine found in:

A-Z Index: